Blog
At present, ibogaine has not been approved as a treatment for any neurodegenerative condition, including Parkinson’s and multiple sclerosis. While our program accommodates individuals with these conditions, it does not treat the conditions themselves; the protocol targets regeneration and an improved quality of life in the long term.
Occasionally, we receive inquiries from individuals living with Amyotrophic Lateral Sclerosis (ALS) who are exploring ibogaine treatment as a potential option.
While we have observed and gathered reports that suggest individuals living with Parkinson’s and MS have found improved quality of life following ibogaine treatment, there is no clinical evidence for ALS which demonstrates that ibogaine definitively alters the course of this condition, reverses neuronal degeneration, or provides consistent therapeutic benefit for it.
While ibogaine has shown neuromodulatory and neuroplasticity-related effects in certain neurological contexts, these findings do not currently support claims of efficacy for ALS or other progressive neurodegenerative diseases. Because of this, Ambio Life Sciences does not present ibogaine as a treatment capable of meaningfully slowing, reversing, or curing ALS or other degenerative neurological conditions.
Should scientific evidence evolve in the future, this position may be reassessed. We deeply respect the challenges faced by individuals and families living with ALS and strongly encourage ongoing collaboration with neurology, rehabilitation, and supportive medicine teams specializing in ALS care.
.jpg)
Patient safety requires that individuals receiving treatment be accommodated in environments that allow for safe mobility, monitoring, and emergency response. Currently, our transportation resources and housing arrangements are not equipped to safely accommodate individuals who rely on motorized wheelchairs or require specialized motorized mobility transport and transfer support. For this reason, we are unfortunately unable to accept patients whose care needs exceed what our current facilities and logistics can safely accommodate.
Currently, our Neuroregenerative Clinic is equipped with accessibility features including ramps and railings, assisted bathing support, and a dedicated around-the-clock clinical team to provide individualized monitoring and care throughout each patient’s stay.
We also receive inquiries from families caring for loved ones living with Alzheimer’s disease or other forms of dementia. We recognize the profound challenges these conditions bring. Dementia affects far more than memory – it impacts communication, judgment, independence, and the ability to meaningfully participate in medical decision-making.
One of the most significant clinical and ethical considerations in these cases is informed consent. As cognitive decline progresses, it can become increasingly difficult for an individual to fully understand treatment risks, benefits, and alternatives. Even when a family member holds medical power of attorney, we must ensure that any treatment we provide meets strict standards for patient comprehension, safety, and ethical medical practice.
Because of these considerations, we cannot provide ibogaine treatment to individuals diagnosed with Alzheimer’s disease, dementia, or other significant cognitive-decline conditions, even when a medical POA is in place. In certain cases, we are open to consultation on an individual basis to review medical history and discuss whether any supportive alternatives may exist.
We understand how difficult and emotional this reality can be for families seeking options. When appropriate, we can offer a consultation with our physician so that families can ask questions, better understand the medical limitations, and explore other avenues of supportive care.
.jpg)
Sharing openly about these limitations is part of our commitment to ethical responsibility, patient safety, and medical transparency. While ibogaine is not currently indicated for ALS, dementia, or other progressive neurodegenerative diseases, we remain deeply committed to advancing responsible research, refining clinical protocols, and contributing to the broader scientific understanding of ibogaine’s therapeutic potential.
Our goal is not only to provide care where appropriate, but to help move the field forward – responsibly, ethically, and in service of the many individuals and families seeking better solutions for complex neurological conditions. For more information on our Neuroregenerative Program, visit the program page. To read stories of patients who have taken ibogaine treatment with neurodegenerative conditions, browse our Success Stories. And to inquire about treatment and speak with a member of our team about the Neuroregenerative Program, apply here.
